ReNeuron Group plc (AIM: RENE) (the ‘Company’), a leading, UK-based stem cell business, is pleased to announce that it will host an investor evening on 27 July 2010
Following on from the Company’s recent preliminary results announcement, this investor update evening will provide private investors with an opportunity to hear about the Company’s progress in stem cell therapy development, the most recent important milestone being the commencement of a UK first-in-man clinical trial of its lead ReN001 stem cell therapy for disabled stroke patients. The event will update investors on ReNeuron’s progress, pipeline development and strategy and will also provide investors with the opportunity to discuss the business with members of the Company’s Board.
If you would like to attend the event, please contact Isabel Podda at Buchanan Communications either via e-mail email@example.com
or via telephone on 020 7466 5000 before Friday 23 July 2010. Places will be limited and there will be no admittance for individuals who have not confirmed their attendance.
– Ends –
Michael Hunt, Chief Executive Officer – ReNeuron +44 (0) 1483 302560
Dr John Sinden, Chief Scientific Officer – ReNeuron
Lisa Baderoon, Mark Court, Isabel Podda
Buchanan Communications +44 (0) 20 7466 5000
Emma Earl, Oliver Rigby
Daniel Stewart & Company plc +44 (0) 20 7776 6550
Alastair Stratton, Tim Graham
Matrix Corporate Capital LLP +44 (0) 20 3206 7000
ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments. ReNeuron’s lead therapeutic candidate is its ReN001 stem cell therapy for patients left disabled by the effects of a stroke. A ground-breaking first-in-man clinical trial of ReN001 has recently commenced in the UK. ReNeuron’s ReN009 stem cell therapy is being developed as a treatment for peripheral arterial disease, a serious and common side-effect of diabetes. The Company is also developing stem cell therapies for other conditions such as blindness-causing diseases of the retina.
ReNeuron has also developed a range of stem cell lines for non-therapeutic applications – its ReNcell® products for use in academic and commercial research. The Company’s ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.
ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.